Accessibility Menu
MiNK Therapeutics logo

MiNK Therapeutics

(NASDAQ) INKT

Current Price$11.26
Market Cap$55.05MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-91%
5 YearN/A
1 Year-83%
1 Month-7%

MiNK Therapeutics Financials at a Glance

Market Cap

$55.05MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$12.47M

EPS (TTM)

-$2.84

P/E Ratio

-3.89

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$11.26

Volume

326

Open

$11.32

Previous Close

$11.26

Daily Range

$11.26 - $11.32

52-Week Range

$8.48 - $52.50

Estimated Earnings Date

Aug 13, 2026

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About MiNK Therapeutics

Industry

Biotechnology

Employees

15

CEO

Jennifer S. Buell, PhD

Headquarters

New York City, NY 10010, US

INKT Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

76.02%

Return on Capital

N/A

Return on Assets

-120.17%

Earnings Yield

-25.71%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$55.05MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

4.98M

Volume

326

Avg. Volume

38.62K

Financials (TTM)

Gross Profit

-$167.05K

Operating Income

-$12.84M

EBITDA

-$12.30M

Operating Cash Flow

-$6.32M

Capital Expenditure

-$3.00

Free Cash Flow

-$6.32M

Cash & ST Invst.

$9.53M

Total Debt

$0.00

MiNK Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$36.07K

+29.0%

Gross Margin

0.00%

N/A

Market Cap

$55.05MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$3.67M

N/A

Employees

15

N/A

Net Income

-$2.74M

+0.9%

EBITDA

-$2.71M

+0.4%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$9.53M

+194.5%

Total Debt

$0.00

-100.0%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

-100.0%

Return on Assets

-1.20%

N/A

Return on Invested Capital

-4.15%

N/A

Free Cash Flow

-$1.73M

+99.9%

Operating Cash Flow

-$1.73M

+99.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
OTLKOutlook Therapeutics, Inc.
$1.55-1.27%
SPRBSpruce Biosciences, Inc.
$48.38-3.38%
NRXPNRx Pharmaceuticals, Inc.
$4.15-0.95%
GANXGain Therapeutics, Inc.
$1.76-2.22%

Trending Stocks

Symbol / CompanyPricePrice Chg
AGENAgenus
$6.12+0.83%
AALAmerican Airlines Group
$16.31-0.04%
ONDSOndas
$6.96-0.04%
NOKNokia
$11.69-0.06%

Questions About INKT

What is the current price of MiNK Therapeutics?

MiNK Therapeutics is trading at $11.26 per share.

What is the 52-week range for MiNK Therapeutics?

Over the past 52 weeks, MiNK Therapeutics has traded between $8.48 and $52.50.

How much debt does MiNK Therapeutics have?

As of the most recent reporting period, MiNK Therapeutics reported total debt of $0.00.

How much cash does MiNK Therapeutics have on hand?

MiNK Therapeutics reported $9.53M in cash and cash equivalents in its most recent financial results.

What is MiNK Therapeutics’s dividend yield?

MiNK Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.